Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    ANI Pharmaceuticals Inc.

    NASDAQ: ANIP · Real-Time Price · USD
    64.33
    1.77 (2.83%)
    At close: Jun 16, 2025, 3:59 PM
    64.29
    -0.06%
    Pre-market: Jun 17, 2025, 08:00 AM EDT

    ANI Pharmaceuticals Statistics

    Share Statistics

    ANI Pharmaceuticals has 21.65M shares outstanding. The number of shares has increased by 3.82% in one year.

    Shares Outstanding

    n/a
    		 21.65M

    Shares Change (YoY)

    n/a
    		 3.82%

    Shares Change (QoQ)

    n/a
    		 3.54%

    Owned by Institutions (%)

    n/a
    		 99.35%

    Shares Floating

    n/a
    		 18.02M

    Failed to Deliver (FTD) Shares

    n/a
    		 10

    FTD / Avg. Volume

    n/a
    		 n/a

    Short Selling Information

    The latest short interest is 1.9M, so 8.79% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 1.9M

    Short % of Shares Out

    n/a
    		 8.79%

    Short % of Float

    n/a
    		 11.05%

    Short Ratio (days to cover)

    n/a
    		 6.26

    Valuation Ratios

    The PE ratio is -57.66 and the forward PE ratio is 8.85. ANI Pharmaceuticals's PEG ratio is 0.3.

    PE Ratio

    n/a
    		 -57.66

    Forward PE

    n/a
    		 8.85

    PS Ratio

    n/a
    		 1.74

    Forward PS

    n/a
    		 1.4

    PB Ratio

    n/a
    		 2.49

    P/FCF Ratio

    n/a
    		 22.69

    PEG Ratio

    n/a
    		 0.3
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for ANI Pharmaceuticals.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 2.72, with a Debt / Equity ratio of 1.46.

    Current Ratio

    n/a
    		 2.72

    Quick Ratio

    n/a
    		 2.02

    Debt / Equity

    n/a
    		 1.46

    Debt / EBITDA

    n/a
    		 7.89

    Debt / FCF

    n/a
    		 13.26

    Interest Coverage

    n/a
    		 0.03

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $684,923.08

    Profits Per Employee

    n/a
    		 $-20,648.83

    Employee Count

    n/a
    		 897

    Asset Turnover

    n/a
    		 0.48

    Inventory Turnover

    n/a
    		 1.83

    Taxes

    Income Tax

    n/a
    		 -3.69M

    Effective Tax Rate

    n/a
    		 16.61%

    Stock Price Statistics

    The stock price has increased by 4.13% in the last 52 weeks. The beta is 0.55, so ANI Pharmaceuticals's price volatility has been higher than the market average.

    Beta

    n/a
    		 0.55

    52-Week Price Change

    n/a
    		 4.13%

    50-Day Moving Average

    n/a
    		 64.84

    200-Day Moving Average

    n/a
    		 60.37

    Relative Strength Index (RSI)

    n/a
    		 57.03

    Average Volume (20 Days)

    n/a
    		 395,544

    Income Statement

    In the last 12 months, ANI Pharmaceuticals had revenue of 614.38M and earned -18.52M in profits. Earnings per share was -0.87.

    Revenue

    n/a
    		 614.38M

    Gross Profit

    n/a
    		 364.17M

    Operating Income

    n/a
    		 584K

    Net Income

    n/a
    		 -18.52M

    EBITDA

    n/a
    		 79.15M

    EBIT

    n/a
    		 -4.61M

    Earnings Per Share (EPS)

    n/a
    		 -0.87
    Full Income Statement

    Balance Sheet

    The company has 144.86M in cash and 624.09M in debt, giving a net cash position of -479.23M.

    Cash & Cash Equivalents

    n/a
    		 144.86M

    Total Debt

    n/a
    		 624.09M

    Net Cash

    n/a
    		 -479.23M

    Retained Earnings

    n/a
    		 -100.28M

    Total Assets

    n/a
    		 1.29B

    Working Capital

    n/a
    		 334.48M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was 64.02M and capital expenditures -16.95M, giving a free cash flow of 47.06M.

    Operating Cash Flow

    n/a
    		 64.02M

    Capital Expenditures

    n/a
    		 -16.95M

    Free Cash Flow

    n/a
    		 47.06M

    FCF Per Share

    n/a
    		 2.44
    Full Cash Flow Statement

    Margins

    Gross margin is 59.27%, with operating and profit margins of 0.1% and -3.01%.

    Gross Margin

    n/a
    		 59.27%

    Operating Margin

    n/a
    		 0.1%

    Pretax Margin

    n/a
    		 -3.62%

    Profit Margin

    n/a
    		 -3.01%

    EBITDA Margin

    n/a
    		 12.88%

    EBIT Margin

    n/a
    		 0.1%

    FCF Margin

    n/a
    		 7.66%

    Dividends & Yields

    ANIP does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for ANIP is $81.5, which is 26.7% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $81.5

    Price Target Difference

    n/a
    		 26.7%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 8
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Stock Splits

    The last stock split was on Jul 18, 2013. It was a backward split with a ratio of 1:6.

    Last Split Date

    n/a
    		 Jul 18, 2013

    Split Type

    n/a
    		 backward

    Split Ratio

    n/a
    		 1:6

    Scores

    Altman Z-Score

    n/a
    		 1.63

    Piotroski F-Score

    n/a
    		 4

    Add to Watchlist